Approval · Notice of Compliance 3540 · 2003
EFFEXOR: Notice of Compliance 3540
Issued April 25, 2003
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 3540
- Date
- April 25, 2003
- Company
- Wyeth CanadaSt. Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revised indication: for maintenance treatment of major depressive disorder
- Therapeutic class
- Antidepressant, anxiolytic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EFFEXOR | Not yet assigned | — |
| EFFEXOR XR | Not yet assigned | — |
Medicinal ingredients
- VENLAFAXINE HYDROCHLORIDE 12.5 MG per TAB
- VENLAFAXINE HYDROCHLORIDE 25 MG per TAB
- VENLAFAXINE HYDROCHLORIDE 37.5 MG per TAB
- VENLAFAXINE HYDROCHLORIDE 50 MG per TAB
- VENLAFAXINE HYDROCHLORIDE 75 MG per TAB
- VENLAFAXINE HYDROCHLORIDE 100 MG per TAB
- VENLAFAXINE HYDROCHLORIDE 37.5 MG per CAP
- VENLAFAXINE HYDROCHLORIDE 75 MG per CAP
- VENLAFAXINE HYDROCHLORIDE 100 MG per CAP
- VENLAFAXINE HYDROCHLORIDE 150 MG per CAP